Next 10 |
home / stock / lgnd / lgnd articles
CHASKA, Minn., July 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contr...
Gilead Sciences, Inc. (NASDAQ: GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a p...
Bristol Myers Squibb (NYSE: BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation...
Shares of Ionis Pharmaceuticals (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) lost at least 2% in market cap on Thursday after the companies announced t...
On May 15, a recent SEC filing unveiled that Matthew E Korenberg, President & Chief Operating at Ligand Pharmaceuticals (NASDAQ:LGND) made an i...
Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor...
Investors might want to bet on Ligand Pharmaceuticals (NASDAQ: LGND), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating...
Perrigo Company plc (NYSE: PRGO) reported adjusted earnings of 29 cents per share in the first quarter of 2024, beating the Zacks Consensus Estimat...
A significant insider transaction involving the exercise of company stock options was reported on March 27, by Todd C Davis, Chief Executive Office...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-09 10:30:11 ET Craig-Hallum analyst issues BUY recommendation for LGND on July 9, 2024 08:42AM ET. The previous analyst recommendation was Buy. LGND was trading at $86.88 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...
2024-07-09 10:00:05 ET Matt Hewitt from Craig-Hallum issued a price target of $140.00 for LGND on 2024-07-09 08:42:00. The adjusted price target was set to $140.00. At the time of the announcement, LGND was trading at $86.88. The overall price target consensus is at $117...
Acquisition provides Ligand with the royalty rights to QARZIBA®, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A. QARZIBA is the sixth key asset added to Ligand’s commercial stage portfolio since the b...